“`html
Novo Nordisk Lowers Prices for Wegovy and ozempic Amidst Competition and Trump Governance Pressure
Table of Contents
Facing increased competition in the weight loss market and intense pressure from the Trump administration, Novo Nordisk is making its blockbuster drugs more accessible to cash-paying customers.
Novo Nordisk announced Monday it is reducing prices for its popular obesity and diabetes medications, Wegovy and Ozempic, for patients who pay out-of-pocket. This move reflects a growing trend among drugmakers to offer direct discounts to consumers and bypass traditional insurance channels, as well as a strategic response to competition from compounding pharmacies offering cheaper alternatives.
Discount Details for Wegovy and Ozempic
The Danish pharmaceutical giant is now offering the first two monthly doses of both Wegovy and Ozempic for $199,a promotional price valid until the end of March. This discount applies to the two lowest available dosages of each medication.
Beyond the introductory offer,Novo Nordisk is further reducing monthly costs for self-pay patients to $349,down from $499. However, the 2-milligram dose of Ozempic will remain priced at $499 per month.
These discounts will be available through Novo Nordisk’s direct-to-consumer channels, as well as through partnerships with major retailers including Costco, GoodRx, and Weight Watchers, and over 70,000 retail pharmacies nationwide.
Deal with the Trump Administration
Novo Nordisk’s pricing adjustments come on the heels of a notable agreement with the Trump administration, alongside rival Eli Lilly. The deal aims to expand access to Medicare and Medicaid in exchange for reduced drug prices.
Under the terms of the agreement, individuals purchasing injectable GLP-1 medications directly from the companies can expect to pay an average of $350 per month initially, with a commitment to lower the price to approximately $250 over the next two years. Should oral GLP-1 tablets receive approval from the U.S. Food and Drug Administration, the lowest dose will be priced at $149.
These reduced prices will become available through TrumpRx, the administration’s new direct-to-consumer online platform, slated to launch in early 2026.
Expanding the Self-Pay Market
Novo Nordisk is strategically focusing on expanding its self-pay channel to bolster sales both domestically and internationally. According to Dave Moore, executive vice president of U.S. operations, the cash market currently represents roughly 10% of total Wegovy prescriptions in the U.S.
“There’s a lot of interest in direct pay, self-pay,” Moore told CNN. “We know that’s an interest of people living with obesity.”
Recent data from a KFF Health Tracking Poll released Friday indicates that approximately 1 in 8 adults are currently using a GLP-1 drug like Ozempic or Wegovy for weight loss or chronic condition management. The poll also revealed that about a quarter of those with insurance coverage are paying the full cost of the medication themselves. Cost is consistently cited as a primary reason for discontinuing use among those who have tried these drugs.
Insurance Coverage and Competition
While Ozempic generally receives broad insurance coverage for diabetes treatment, coverage for Wegovy specifically for weight loss remains limited, largely due to its high list price of $1,349 per month.Novo Nordisk launched its direct-to-consumer pharmacy earlier this year, initially offering Wegovy at $499 per month, and began selling Ozempic at a reduced cash price of $499 in August.
Eli Lilly has also responded to the competitive landscape by lowering the price of its GLP-1 weight loss drug, Zepbound, for self-pay patients.
Did you know?-GLP-1 drugs like Wegovy and Ozempic work by mimicking a natural hormone that regulates appetite and blood sugar. They can lead to significant weight loss and improved metabolic health when combined with lifestyle changes.
Pro tip:-Check with
